Predictive Presymptomatic Testing Market

Global Predictive Presymptomatic Testing Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2026-2033

Statistics:

• Global Presymptomatic Testing Market was worth USD 6.88 billion in 2026
• Is projected to amass a valuation of USD 13.06 billion by 2033
• Registering a CAGR of 9.58% over 2026-2033

The Worldwide Predictive Presymptomatic Testing Industry dynamics have been evaluated by taking various market-based aspects into account. In this report, 2021 has been taken as the base year. Further, the forecast period of 2022-2029 has been considered for the overall market analysis.

Scope:

Presymptomatic and predictive testing is the type of genetic testing for people having history of a condition which can be done for detection of risk for developing that condition. Predictive testing can detect mutations that increase a person’s risk of developing disorders with a genetic basis, such as certain types of cancer and help with making decisions about medical care. Number of heritable genetic disorders including hereditary cancer syndromes, inherited cardiac conditions and neurodegenerative genetic disorders can be detected by presymptomatic and predictive genetic testing. 

COVID-19 Impact:

The COVID-19 pandemic has shown negative impact on the global predictive presymptomatic testing. Due to spread of the COVID-19 pandemic, most clinics and hospitals have constrained in-person delivery of non-essential healthcare services, including genetic counselling, to slow the spread of the virus. The limit the spread of virus and its treatment was the main priority during pandemic. 

Competitive Hierarchy:

The prominent players characterizing the competitive terrain of this business sphere are-

• 23andMe Inc.
• Mapmygenome
• Abbott Molecular Inc.
• BioAxis DNA Research Centre Private Limited
• Gene by Gene Ltd.
• Pathway Genomics Corporation
• Color Genomics Inc.
• Myriad Genetics Inc.
• Positive Bioscience Inc.
• Quest Diagnostics Inc
• Abbott Laboratories
• Bayer HealthCare AG
• Biocartis SA
• BioHelix Corporation
• bioMerieux S.A.
• Celera Corporation
• Cepheid
• Daan Diagnostics Ltd.
• EKF Diagnostics Holdings plc
• others

Segmentation: 

By Condition:

• Colorectal Cancer
• Alzheimer's Disease
• Multiple Endocrine Neoplasia Type 2
• Haemochromatosis
• Breast and Ovarian Cancer

The breast and ovarian cancer segment is presently dominating the marketplace in terms of volume share. This is attributable to the growing prevalence of these target ailments. These diseases are controlled by genes and can be passed from one generation to another. Therefore, presymptomatic testing can be used to determine if an individual is at a risk of developing ovarian or breast cancer. If found positive, they can immediately opt for preventive care.

By Region:

North America

• U.S.
• Canada

Europe

• Germany
• France
• K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Switzerland
• Belgium
• Rest of Europe

Asia-Pacific

• South Korea
• Japan
• China
• India
• Australia
• Philippines
• Singapore
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Colombia
• Brazil
• Argentina
• Peru
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Geographical Landscape:

Expounding the geographical terrain of this market

North America- North America is expected to dominate the global predictive presymptomatic testing due to increasing prevalence of breast cancer, technological advancements and rising awareness about predictive and presymptomatic testing. For example, according to Breastcancer.org, there are more than 3.8 million women with a history of breast cancer in the U.S. In addition, advanced healthcare facilities with developed infrastructure are also boosting the market growth of predictive and presymptomatic testing in this region. 

Asia Pacific- Asia Pacific is expected to be second largest market for the global predictive presymptomatic testing market due to increasing population, rising disposable income, and growing demand for genetic testing in this region.  Apart from that, increasing prevalence of cancer, rising R&D investments in the field, along with the ever-growing healthcare expenditure in the field are further adding traction to the development of this regional market.

MEA- The Middle East and Africa region is expected to garner substantial returns over the assessment timeline. Countries in the Middle Eastern region are experiencing robust developments in terms of their healthcare infrastructure. Due to widespread economic developments, high end disease diagnosis and treatment facilities are being incorporated in almost every healthcare centre. Alongside, numerous nations in Africa are struggling to get the bare minimum in terms of healthcare. The disease burden is also high in this region. Hence, government bodies and welfare organizations from across the globe are taking keen interest to do their best to improve the healthcare scenario in the African region. This in turn is creating endless possibilities for this market to bolster in the African region as well.

Major growth drivers:

• Increasing prevalence of breast cancer
• Rising demand for genetic counselling
• Growing R&D initiatives for novel therapeutics

Key Trends

Increasing prevalence of breast  cancer is aiding industry  expansion

One of the major factors driving the growth of the global predictive presymptomatic testing market is increasing prevalence of breast cancer. For instance; according to World Health Organisation (WHO) there have been 2.3 million women diagnosed with breast cancer and 685 000 deaths globally in 2020. With the help of predictive presymptomatic testing breast cancer is identified early. Thus, increasing prevalence of breast cancer is increasing the growth of predictive presymptomatic testing for the disease detection for the forecast period.

Escalating demand for genetic counselling  is bolstering market growth

Rising demand for genetic counselling is also supplementing the market growth. Genetic counselling is for understanding and adapting the medical, psychological and familial implications of genetic contributions to disease. Rising knowledge and awareness about genetic counselling for inherited disorders is also augmenting the demand for the predictive and presymptomatic testing. 

Surging R&D activities  is the field to spur industry progression

Moreover, growing research and development activities in this field are also fostering the market growth. For example; on January 10th, 2022 FDA approved 23andMe direct-to-consumer genetic test on a hereditary prostate cancer marker. However, expensive predictive presymptomatic testing technologies may hamper the market growth. In spite of that, research and development will provide more opportunities for the further growth of the market. 

Major Developments

Predictive Genetic Test for Type 2 Diabetes Being Implemented in COVID-19 Patient Care Protocols

On January 21st, 2021; DIABETES predicts, a primary of its kind predictive genetic test for type 2 diabetes, is being administered to assist improve patient outcomes during the COVID-19 pandemic. In step with a recent study on the bidirectional relationship of type 2 diabetes and COVID-19, patients with type 2 diabetes are predisposed to adverse clinical outcomes from the COVID-19 virus. additionally, many COVID-19 patients are found to develop new onset diabetes after infection. Type 2 diabetes genetic risk can be detected by DIABETES predict.